Cargando…
ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析
BACKGROUND AND OBJECTIVE: In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently repor...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519956/ https://www.ncbi.nlm.nih.gov/pubmed/32752580 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.07 |